Supernus Pharmaceuticals
SUPN
235 hedge funds and large institutions have $1.22B invested in Supernus Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 80 increasing their positions, 87 reducing their positions, and 35 closing their positions.
11% more call options, than puts
Call options by funds: $8.4M | Put options by funds: $7.54M
1.48% more ownership
Funds ownership: 96.32% → 97.81% (+1.5%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 35
8% less repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 87
3% less funds holding
Funds holding: 243 → 235 (-8)
11% less capital invested
Capital invested by funds: $1.37B → $1.22B (-$150M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$41.6M |
| 2 |
Morgan Stanley
New York
|
+$17.7M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$16.8M |
| 4 |
First Manhattan
New York
|
+$13.7M |
| 5 |
BlackRock
New York
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
-$17.2M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$15.4M |
| 3 |
NPIC
Neumeier Poma Investment Counsel
Carmel,
California
|
-$15.1M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$11.7M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$11.2M |
SUPN Hedge Fund Activity: Q4 2019 in Review
235 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q4 2019, worth a combined $1.22B — down 11% from $1.37B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of SUPN and 34 opened new positions — a net loss of 1 holder — while 87 trimmed existing stakes and 80 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $41.6M. The largest seller was Champlain Investment Partners, exiting entirely with an estimated $17.2M sold.
- 235 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q4 2019, down from 243 in Q3 2019.
- Funds reported $1.22B of Supernus Pharmaceuticals stock for Q4 2019, down 11% quarter-over-quarter.
- 34 funds opened new Supernus Pharmaceuticals positions in Q4 2019 and 35 closed out, a net change of -1 holder.
- The largest Supernus Pharmaceuticals buyer in Q4 2019 was Armistice Capital, an estimated $41.6M added.
- The largest Supernus Pharmaceuticals seller in Q4 2019 was Champlain Investment Partners, an estimated $17.2M sold.
Based on aggregated 13F filings for Q4 2019.